Medical and socio-economical impact of drug-induced adverse reactions;Conséquences médicales et socio-économiques des effets indésirables médicamenteux

Presse Medicale

Volumn 34, Issue 4, 2005, Pages 271-276

  Apretna, Edwige ^a   Haramburu, Françoise ^a,b   Taboulet, Florence ^a   Bégaud, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN II ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN DERIVATIVE; HYPNOTIC AGENT; MORPHINE DERIVATIVE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TUBERCULOSTATIC AGENT;

ADULT; ANAPHYLAXIS; ARTICLE; CONVULSION; COST OF ILLNESS; DRUG INDUCED DISEASE; ECONOMIC ASPECT; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; SKIN TOXICITY;

EID: 14644407541     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)83904-1     Document Type: Article

References (31)

1. Lawson DH, Hutcheon AW, Jick H. Life threatening drug reactions amongst medical in-patients. Scot Med 1979; 24: 127-30.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
3. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-8.
4. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847-51.
5. Harb GE, Alldredge BK, Coleman R, Jacobson MA. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1993; 6: 919-26.
6. Jick H. Drugs remakably nontoxic. N Engl J Med 1974; 291: 824-8.
7. Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA 1974; 228: 713-7.
8. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related ressource use. A study of community-dwelling persons 65 years of age and older. Ann Intern Med 1992; 117: 634-40.
9. Prince BS, Goetz CM, Rihn TL, Olsky M. Drug-related emergency department visits and hospital admissions. Am J Hosp Pharm 1992; 49: 1696-700.
10. Schneider JK, Mion LC, Frengley JD. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90-6.
11. Directive 2000/38/CE du 5 juin 2000 modifiant le chapitre V bis (Pharmacovigilance) de la directive 75/319/CEE du Conseil concernant le rapprochement des dispositions législatives, réglementaires et administratives relatives aux spécialités pharmaceutiques. Journal Officiel des Communautés Européennes, 10.6.2000.
12. Auray JP, Bail JN, Béraud C, et al. Recommandations de bonnes pratiques des méthodes d'évaluation économique des stratégies thérapeutiques. J Economie Med 1998; 4-5: 329-51.
13. Nomenclature générale des actes professionnels Union des caisses nationales de Securité Sociales. Mise à jour n°3 1999.
14. CNAMTS. Indicateur statistique 1998-1999: 161.
15. Haramburu F, Tubert-Bitter P, Bégaud B. Trends in spontaneous reporting. Post-Marketing Surveillance 1992; 6: 129-34.
16. Moride Y, Haramburu F, Requejo Alvarez A, Bégaud B. Under reporting of adverse drug reaction in general practice. Br J Clin Pharmacol 1997; 43: 177-81.
17. Haramburu F, Bégaud B, Moride Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol 1997; 44: 299-301.
18. Les Français, la maladie et le risque thérapeutique. Concours Med 1990; 112: 241.
19. Lacoste-Roussillon C, Pouyanne P, Haramburu F, Miremont G, Bégaud B. Incidence of serious adverse drug reactions in general practice: a prospective study. Clin Pharmacol Ther 2001; 69: 458-62.
20. Chan TYK, Critchley JAJ. Drug related problems as a cause of hospital admissions in Hong Kong. Drug Saf 1995; 4: 165-70.
21. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832-40.
22. Imbs JL, Pouyanne P, Haramburu F, Welsch M, Decker N, Blayac JP et al. latrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics françis. Therapie 1999; 54: 21-7.
23. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036.
24. Chan TYK Chan JCN, Tomlinson B, Critchley JAJH. Adverse reactions to drugs as a cause of admissions to a general teaching hospital in Hong Kong. Drug Saf 1992; 7: 235-40.
25. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra-costs, and attributable mortality. JAMA 1997; 277: 301-6.
26. Perault MC, Pinellei AL, Chauveau I, Scepi M, Remblier C, Vandel B. Enquête prospective sur les admissions pour iatrogénie médicamenteuse dans le service d'accueil des urgences du centre hospitalier universitaire de Poitiers. Therapie 1999; 54: 183-5.
27. Detournay B, Fagnani F, Pouyanne P, Haramburu F, Begaud B, Welsch M et al. Coût des hospitalisations pour effet indésirable médicamenteux. Therapie 2000; 55: 137-9.
28. Vargas E, Simonn J, Martin JC et al. Effect of adverse drug reactions on length of stay in intensive care units. Clin Drug Invest 1998; 15: 353-60.
29. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring - Cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6: S79-S90.
30. Imbs JL, Pletan Y, Spriet A et les participants à la Table Ronde n°2 de Giens XIII. Évaluation de la iatrogenèse médicamenteuse évitable: méthodologie. Therapie 1998; 5: 365-70.
31. Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf 2002; 25: 1035-44.